ARTICLE: Severe obesity in human HFpEF alters contractile protein function and organization
AUTHORS: Vivek P Jani, Marcus Rhodehamel, Axel J Fenwick, Weikang Ma, Eli Fisher, Maria T Giannakopoulos, Sun Moon, Romi L Castillo, Leslie M Kennedy, Thomas C Irving, Jil C Tardiff, Elizabeth Murphy, Raghothama Chaerkady, Qing Wang, Meaghan E Barry, Virginia S Hahn, Kavita Sharma, Kenneth B Margulies, Kenneth C Bedi Jr, Anthony Cammarato, David A Kass
JOURNAL: Science. 2026 Jun 4;392(6802):eadz7118. doi: 10.1126/science.adz7118. Epub 2026 Jun 4.
Abstract
Heart failure with preserved ejection fraction (HFpEF) causes substantial morbidity and mortality and has few effective therapies. Its phenotype has changed over time, with morbid obesity and metabolic defects supplanting hypertension and cardiac hypertrophy. We reveal that cardiomyocytes from patients with severe obesity and HFpEF have very depressed contractile reserve, including reduced calcium- and length-stimulated tension, power, and myosin activation compared with less-obese HFpEF and nonfailing (NF) controls with or without obesity but similar to those with advanced HF and reduced ejection fraction. Myocyte defects correlate with body mass index and exercise hemodynamics in patients with HFpEF but not NF and appear reversible upon weight loss. Increased troponin I phosphorylation at threonine 181 occurs only in heart failure with obesity, contributing to sarcomere dysfunction. Weight reduction and sarcomere enhancers may offer benefits in HFpEF with obesity.
For the full article, click here.
For a link to the abstract, click here.
